No results for ‘’
Windlas Biotech Ltd
₹829.45
(0.71%)
Wed, 17 Jun 2026, 04:12 am
Health Technology
Pharmaceuticals: Major
24.5KWindlas Biotech Price to Sales Ratio (P/S)
| Particulars | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 11.31 | 11.43 | 18.38 | 36.07 |
| Price to book ratio | 0 | 0 | 0 | 0 | 1.16 | 1.17 | 2.37 | 4.31 |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0.93 | 0.95 | 1.70 | 2.90 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 41.90 | 7.53 | 9.76 | 33.62 |
| Enterprise value | 0 | 0 | 0 | 0 | 259Cr | 360Cr | 869Cr | 1993Cr |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 0 | 4.98 | 5.95 | 11.04 | 21.05 |
| Debt to equity ratio | 0.46 | 0.16 | 0.14 | 0.16 | 0.02 | 0.01 | 0.01 | 0.06 |
| Return on equity % | 0 | 40.06 | 8.04 | 7.75 | 12.83 | 10.70 | 13.66 | 12.76 |
Windlas Biotech Ltd Price to Sales Ratio
The Windlas Biotech Ltd Price to Sales Ratio is a key financial metric used by investors to evaluate Windlas Biotech Ltd's valuation, profitability, and overall financial performance. Tracking the Windlas Biotech Ltd Price to Sales Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Windlas Biotech Ltd (NSE: WINDLAS, BSE: 543329) is currently trading at ₹829.45, with a market capitalization of ₹1719.2Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Windlas Biotech Ltd Price to Sales Ratio is essential for fundamental analysis.
Windlas Biotech Ltd Price to Sales Ratio Current Value
The current Windlas Biotech Ltd Price to Sales Ratio stands at 2.90.
The latest Windlas Biotech Ltd Price to Sales Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Windlas Biotech Ltd Price to Sales Ratio Historical Trend
The Windlas Biotech Ltd Price to Sales Ratio has shown the following historical trend:
- 2024: 2.90
- 2023: 1.70
- 2022: 0.95
- 2021: 0.93
- 2020: 0
The recent rise in Windlas Biotech Ltd Price to Sales Ratio suggests strengthening valuation trends and improving market sentiment.
What Windlas Biotech Ltd Price to Sales Ratio Indicates for Investors
The Windlas Biotech Ltd Price to Sales Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/S ratio helps evaluate valuation relative to company revenue.
Windlas Biotech Ltd Price to Sales Ratio Analysis Summary
The Windlas Biotech Ltd Price to Sales Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Windlas Biotech Ltd Price to Sales Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Windlas Biotech Ltd Price to Sales Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.